Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer

Keiji Matsumoto, Tomonari Sasaki, Yoshiyuki Shioyama, Katsumasa Nakamura, Kazushige Atsumi, Takeshi Nonoshita, Saiji Ooga, Tadamasa Yoshitake, Satoru Uehara, Hideki Hirata, Hiroshi Honda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: The aim of the study was to investigate the outcomes of high-dose-rate interstitial radiation therapy for patients with Stage I and II mobile tongue cancer retrospectively. Methods: Sixty-seven patients with Stage I and II mobile tongue cancer were treated with highdose- rate interstitial radiation therapy, with or without external beam radiation therapy, between 1997 and 2007. The median dose of interstitial radiation therapy was 50 Gy in 10 fractions over 6 days. Thirty-five patients received external beam radiation therapy before interstitial radiation therapy. The median dose of external beam radiation therapy was 20 Gy delivered with singlelateral or bilateral fields, including the primary tumor site and upper jugular lymph nodes. Thirtyseven patients received concurrent chemotherapy, including carboplatin, cisplatin, fluorouracil or tegafur, gimeracil and oteracil (TS-1) systemically or with intra-arterial injection. Thirty-three patients received intratumoral injection of bleomycin before catheter insertion. The median follow-up time was 58.6 months (range 15.1-102.4 months). Results: The 5-year overall, cause-specific, progression-free survival rate and local control rate were 88.7, 92.1, 76.0 and 94.0%, respectively. Fourteen patients developed cervical lymph node recurrence, 11 of which were distributed within the external beam radiation therapy field. We found local failures in four cases within 2 years after the treatment and in three cases after 7 years, even though the latter were difficult to distinguish from second primary cancers. Conclusions: The treatment results of our institutions were equivalent to previous reports. Most cervical lymph node metastases occurred within the external beam radiation therapy field, which implied that the external beam radiation therapy dose of 20-30 Gy was insufficient to prevent late cervical lymph node metastases.

Original languageEnglish
Article numberhyt108
Pages (from-to)1012-1017
Number of pages6
JournalJapanese journal of clinical oncology
Volume43
Issue number10
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Tongue Neoplasms
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Intra-Arterial Injections
Second Primary Neoplasms
Carboplatin
Bleomycin
Fluorouracil
Cisplatin
Disease-Free Survival
Neck
Catheters
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer. / Matsumoto, Keiji; Sasaki, Tomonari; Shioyama, Yoshiyuki; Nakamura, Katsumasa; Atsumi, Kazushige; Nonoshita, Takeshi; Ooga, Saiji; Yoshitake, Tadamasa; Uehara, Satoru; Hirata, Hideki; Honda, Hiroshi.

In: Japanese journal of clinical oncology, Vol. 43, No. 10, hyt108, 01.10.2013, p. 1012-1017.

Research output: Contribution to journalArticle

Matsumoto, Keiji ; Sasaki, Tomonari ; Shioyama, Yoshiyuki ; Nakamura, Katsumasa ; Atsumi, Kazushige ; Nonoshita, Takeshi ; Ooga, Saiji ; Yoshitake, Tadamasa ; Uehara, Satoru ; Hirata, Hideki ; Honda, Hiroshi. / Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer. In: Japanese journal of clinical oncology. 2013 ; Vol. 43, No. 10. pp. 1012-1017.
@article{77a1fe8966db4b7c91387777b28b706d,
title = "Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer",
abstract = "Objectives: The aim of the study was to investigate the outcomes of high-dose-rate interstitial radiation therapy for patients with Stage I and II mobile tongue cancer retrospectively. Methods: Sixty-seven patients with Stage I and II mobile tongue cancer were treated with highdose- rate interstitial radiation therapy, with or without external beam radiation therapy, between 1997 and 2007. The median dose of interstitial radiation therapy was 50 Gy in 10 fractions over 6 days. Thirty-five patients received external beam radiation therapy before interstitial radiation therapy. The median dose of external beam radiation therapy was 20 Gy delivered with singlelateral or bilateral fields, including the primary tumor site and upper jugular lymph nodes. Thirtyseven patients received concurrent chemotherapy, including carboplatin, cisplatin, fluorouracil or tegafur, gimeracil and oteracil (TS-1) systemically or with intra-arterial injection. Thirty-three patients received intratumoral injection of bleomycin before catheter insertion. The median follow-up time was 58.6 months (range 15.1-102.4 months). Results: The 5-year overall, cause-specific, progression-free survival rate and local control rate were 88.7, 92.1, 76.0 and 94.0{\%}, respectively. Fourteen patients developed cervical lymph node recurrence, 11 of which were distributed within the external beam radiation therapy field. We found local failures in four cases within 2 years after the treatment and in three cases after 7 years, even though the latter were difficult to distinguish from second primary cancers. Conclusions: The treatment results of our institutions were equivalent to previous reports. Most cervical lymph node metastases occurred within the external beam radiation therapy field, which implied that the external beam radiation therapy dose of 20-30 Gy was insufficient to prevent late cervical lymph node metastases.",
author = "Keiji Matsumoto and Tomonari Sasaki and Yoshiyuki Shioyama and Katsumasa Nakamura and Kazushige Atsumi and Takeshi Nonoshita and Saiji Ooga and Tadamasa Yoshitake and Satoru Uehara and Hideki Hirata and Hiroshi Honda",
year = "2013",
month = "10",
day = "1",
doi = "10.1093/jjco/hyt108",
language = "English",
volume = "43",
pages = "1012--1017",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer

AU - Matsumoto, Keiji

AU - Sasaki, Tomonari

AU - Shioyama, Yoshiyuki

AU - Nakamura, Katsumasa

AU - Atsumi, Kazushige

AU - Nonoshita, Takeshi

AU - Ooga, Saiji

AU - Yoshitake, Tadamasa

AU - Uehara, Satoru

AU - Hirata, Hideki

AU - Honda, Hiroshi

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Objectives: The aim of the study was to investigate the outcomes of high-dose-rate interstitial radiation therapy for patients with Stage I and II mobile tongue cancer retrospectively. Methods: Sixty-seven patients with Stage I and II mobile tongue cancer were treated with highdose- rate interstitial radiation therapy, with or without external beam radiation therapy, between 1997 and 2007. The median dose of interstitial radiation therapy was 50 Gy in 10 fractions over 6 days. Thirty-five patients received external beam radiation therapy before interstitial radiation therapy. The median dose of external beam radiation therapy was 20 Gy delivered with singlelateral or bilateral fields, including the primary tumor site and upper jugular lymph nodes. Thirtyseven patients received concurrent chemotherapy, including carboplatin, cisplatin, fluorouracil or tegafur, gimeracil and oteracil (TS-1) systemically or with intra-arterial injection. Thirty-three patients received intratumoral injection of bleomycin before catheter insertion. The median follow-up time was 58.6 months (range 15.1-102.4 months). Results: The 5-year overall, cause-specific, progression-free survival rate and local control rate were 88.7, 92.1, 76.0 and 94.0%, respectively. Fourteen patients developed cervical lymph node recurrence, 11 of which were distributed within the external beam radiation therapy field. We found local failures in four cases within 2 years after the treatment and in three cases after 7 years, even though the latter were difficult to distinguish from second primary cancers. Conclusions: The treatment results of our institutions were equivalent to previous reports. Most cervical lymph node metastases occurred within the external beam radiation therapy field, which implied that the external beam radiation therapy dose of 20-30 Gy was insufficient to prevent late cervical lymph node metastases.

AB - Objectives: The aim of the study was to investigate the outcomes of high-dose-rate interstitial radiation therapy for patients with Stage I and II mobile tongue cancer retrospectively. Methods: Sixty-seven patients with Stage I and II mobile tongue cancer were treated with highdose- rate interstitial radiation therapy, with or without external beam radiation therapy, between 1997 and 2007. The median dose of interstitial radiation therapy was 50 Gy in 10 fractions over 6 days. Thirty-five patients received external beam radiation therapy before interstitial radiation therapy. The median dose of external beam radiation therapy was 20 Gy delivered with singlelateral or bilateral fields, including the primary tumor site and upper jugular lymph nodes. Thirtyseven patients received concurrent chemotherapy, including carboplatin, cisplatin, fluorouracil or tegafur, gimeracil and oteracil (TS-1) systemically or with intra-arterial injection. Thirty-three patients received intratumoral injection of bleomycin before catheter insertion. The median follow-up time was 58.6 months (range 15.1-102.4 months). Results: The 5-year overall, cause-specific, progression-free survival rate and local control rate were 88.7, 92.1, 76.0 and 94.0%, respectively. Fourteen patients developed cervical lymph node recurrence, 11 of which were distributed within the external beam radiation therapy field. We found local failures in four cases within 2 years after the treatment and in three cases after 7 years, even though the latter were difficult to distinguish from second primary cancers. Conclusions: The treatment results of our institutions were equivalent to previous reports. Most cervical lymph node metastases occurred within the external beam radiation therapy field, which implied that the external beam radiation therapy dose of 20-30 Gy was insufficient to prevent late cervical lymph node metastases.

UR - http://www.scopus.com/inward/record.url?scp=84885153367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885153367&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt108

DO - 10.1093/jjco/hyt108

M3 - Article

VL - 43

SP - 1012

EP - 1017

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

M1 - hyt108

ER -